Tocilizumab in severe to critically ill COVID-19 patients: does timing matter?
Abstract Purpose Tocilizumab reduces inflammation during cytokine storms, a key driver of acute respiratory distress syndrome (ARDS) in COVID-19. This study evaluates the impact of tocilizumab timing on outcomes in severe to critically ill COVID-19 patients. Methods This prospective study included p...
Furkejuvvon:
| Váldodahkkit: | , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Springer
2025-09-01
|
| Ráidu: | Egyptian Journal of Critical Care Medicine |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1007/s44349-025-00026-0 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|